双鹭药业(002038) - 2020 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2020 was ¥194,660,284.30, a decrease of 58.19% compared to ¥465,621,600.26 in the same period last year[10] - Net profit attributable to shareholders for Q1 2020 was ¥61,582,818.21, down 69.29% from ¥200,556,922.20 year-on-year[10] - Basic and diluted earnings per share for Q1 2020 were both ¥0.0599, a decrease of 79.54% compared to ¥0.2928 in the same period last year[10] - The company's operating profit for the current period is ¥66,456,836.55, a significant decrease from ¥224,923,904.02 in the previous period, reflecting a decline of approximately 70.5%[62] - The total profit for the current period is ¥66,412,925.50, down from ¥224,970,456.02, indicating a decrease of about 70.5%[62] - The company's total comprehensive income for the current period is ¥66,763,094.26, down from ¥195,465,576.96, a decrease of about 65.8%[65] - The company's operating revenue for the current period is ¥191,987,002.87, a decrease of 58.8% from ¥465,022,711.65 in the previous period[66] Cash Flow and Investments - The net cash flow from operating activities was ¥41,129,600.32, representing an 80.51% decline from ¥210,979,582.78 in the previous year[10] - Cash flow from operating activities is ¥295,809,369.17, down from ¥522,666,752.32, indicating a decline of about 43.5%[73] - The total cash outflow from investing activities was 503,023,391.93, compared to 74,483,089.44 in the previous period, representing an increase of approximately 576.5%[76] - The net cash flow from investing activities was -498,296,947.00, a substantial decline from -67,496,213.49 in the previous period, reflecting a worsening investment position[76] - The cash inflow from investment activities was 4,726,444.93, down from 6,986,875.95 in the previous period, showing a decrease of approximately 32.3%[83] - The cash outflow for the acquisition of fixed assets and other long-term assets was 6,077,028.12, compared to 13,986,541.58 in the previous period, indicating a reduction of approximately 56.5%[83] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,307,454,317.56, an increase of 1.58% from ¥5,224,966,177.85 at the end of the previous year[10] - The company's total assets increased from 5,224,966,177.85 yuan at the end of 2019 to 5,307,454,317.56 yuan as of March 31, 2020[43] - The company's total liabilities decreased from 403,757,007.80 yuan at the end of 2019 to 376,308,179.66 yuan as of March 31, 2020[46] - Total liabilities decreased to CNY 270,728,873.86 from CNY 286,248,984.20, a reduction of about 5.4%[56] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 55,090, with the top ten shareholders holding significant stakes[15] - Net assets attributable to shareholders increased by 2.29% to ¥4,918,282,636.75 from ¥4,808,196,812.66 at the end of the previous year[10] - The total equity attributable to shareholders increased to CNY 4,918,282,636.75 from CNY 4,808,196,812.66, reflecting a growth of approximately 2.3%[49] Government Support and Other Income - The company received government subsidies amounting to ¥4,006,392.86 during the reporting period[10] - Non-recurring gains and losses totaled ¥18,761,216.75 after accounting for tax effects of ¥3,310,802.96[10] Research and Development - The company reported R&D expenses of CNY 28,032,869.66, an increase from CNY 22,397,212.53, indicating a focus on innovation[59] - Research and development expenses increased to ¥28,195,343.26 from ¥22,627,600.66, marking an increase of approximately 24%[66] Market Strategy - The company aims to expand its market presence and enhance product development strategies in the upcoming quarters[56]